Method diagnosis of a prenatal disorder by selective determination of placental growth factor 2
AssigneeCezanne S.A.S.
InventorsGaïané Demirdjian, Delphine Espinasse
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunoassay method for placental growth factor 2 (PlGF-2) detection in pregnant subjects. Furthermore the invention relates to the use of said method for the diagnosis, prognosis, risk assessment and therapy control of prenatal disorders comprising the determination of the level of PlGF-2 in said pregnant subjects.
Claims5
A method for the diagnosis, prognosis, risk assessment, and/or risk stratification of preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate in a pregnant female subject, comprising an immunoassay method for the detection of placental growth factor 2 (PlGF-2) comprising:
- (a) contacting a sample suspected of comprising PlGF-2 with a first antibody or an antigen-binding fragment thereof specific for PlGF and a second antibody or an antigen-binding fragment thereof, specific for PlGF-2 under conditions allowing for the formation of a ternary complex between PlGF-2 and the two antibodies or antigen-binding fragments thereof,
- wherein the first antibody is an antibody provided by R&D Systems Europe Ltd. Abingdon UK under Ref. No.:
- AF-264-PB (polyclonal anti-PlGF antibody),
- wherein the second antibody is the antibody which is produced by a hybridoma cell line selected from the group consisting of the cell line 477/G2 deposited as DSM ACC3222 and the cell line 477/ES deposited as DSM ACC3221;
- (b) detecting the binding of the two antibodies or antigen-binding fragments thereof to PlGF-2;
- (c) determining the level of placental growth factor 2 (PlGF-2) in a sample from the subject;
- and
- (d) comparing the determined level in the sample to a control level of PlGF-2 derived from subjects without preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate;
- wherein a decreased level of PlGF-2 in the sample from the subject as compared to the control level is indicative for preeclampsia, increased risk of acquiring preeclampsia, increased risk of aggravation of preeclampsia, increased risk of delivery of a child with an aneuploidy, increased risk of an aggravation of the risk of delivery of a child with an aneuploidy, increased risk of delivery of a small for gestational age neonate, and/or increased risk of an aggravation of the risk of delivery of a small for gestational age neonate.
A method for the diagnosis, prognosis, risk assessment, and/or risk stratification of preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate in a pregnant female subject, comprising an immunoassay method for the detection of placental growth factor 2 (PlGF-2) comprising:
- (a) contacting a sample suspected of comprising PlGF-2 with a first antibody or an antigen-binding fragment thereof specific for PlGF and a second antibody or an antigen-binding fragment thereof, specific for PlGF-2,
- wherein the first antibody is an antibody provided by R&D Systems Europe Ltd. Abingdon UK under Ref. No.:
- AF-264-PB (polyclonal anti-PlGF antibody),
- wherein the second antibody is the antibody produced by a hybridoma cell line selected from the group consisting of the cell line 477/G2 deposited as DSM ACC3222 and the cell line 477/ES deposited as DSM ACC3221;
- (b) detecting the binding of the two antibodies or antigen-binding fragments thereof to PlGF-2;
- (c) determining the level of placental growth factor 2 (PlGF-2) in a sample from the subject;
- and
- (d) comparing the determined level in the sample to a control level of PlGF-2 derived from subjects without preeclampsia, or the risk of delivery of a child with an aneuploidy, or the risk of delivery of a small for gestational age neonate;
- wherein a decreased level of PlGF-2 in the sample from the subject as compared to the control level is indicative for preeclampsia, increased risk of acquiring preeclampsia, increased risk of aggravation of preeclampsia, increased risk of delivery of a child with an aneuploidy, increased risk of an aggravation of the risk of delivery of a child with an aneuploidy, increased risk of delivery of a small for gestational age neonate, and/or increased risk of an aggravation of the risk of delivery of a small for gestational age neonate.
Dependencies are inferred from the claim text.